Solaris Pharma Corporation located in Bridgewater, New Jersey announces final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Clobetasol Propionate Cream USP, 0.05% in the following packaging configurations, 15 g, 30 g, 45 g and 60 g tubes. For more updates, please feel free to email us info@solaris-pharma.com
News &
Events
Updated: June 2, 2026
Solaris Pharma Receives FDA Approval for Clobetasol Propionate Cream USP, 0.05%
About Solaris
Solaris Pharma Corporation, A Privately Held Company Headquartered In Bridgewater, NJ, Is A Specialty Pharmaceutical Company Developing And Commercializing High Value Drug Products With Limited Generic Competitors. Solaris Is Committed To Development Of Complex Dosage Forms And 505(B)(2) Products That Bring Value To Patients By Providing Access To Quality, Affordable Medicine.
Contact
Shalin Jani
CEO
Info@Solaris-Pharma.com
Source: Solaris Pharma Corporation
Press Release
